William Blair Has Pessimistic Outlook of LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMRFree Report) – Investment analysts at William Blair lowered their Q1 2025 earnings estimates for Larimar Therapeutics in a research note issued on Monday, December 16th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their prior estimate of ($0.32). William Blair has a “Outperform” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.16) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($1.81) EPS, FY2027 earnings at ($1.83) EPS and FY2028 earnings at ($0.19) EPS.

Larimar Therapeutics (NASDAQ:LRMRGet Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.13. During the same period last year, the business posted ($0.21) EPS.

A number of other brokerages have also recently issued reports on LRMR. Wedbush began coverage on shares of Larimar Therapeutics in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 target price for the company. Baird R W upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Robert W. Baird began coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Larimar Therapeutics in a research report on Monday. Finally, Oppenheimer initiated coverage on Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 price objective on the stock. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.43.

Read Our Latest Analysis on Larimar Therapeutics

Larimar Therapeutics Price Performance

Larimar Therapeutics stock traded down $0.06 during trading hours on Thursday, hitting $4.10. The company had a trading volume of 156,845 shares, compared to its average volume of 620,811. The firm has a market cap of $261.61 million, a PE ratio of -3.57 and a beta of 0.86. Larimar Therapeutics has a one year low of $3.01 and a one year high of $13.68. The firm has a 50-day moving average of $7.03 and a 200 day moving average of $7.68.

Institutional Investors Weigh In On Larimar Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of Larimar Therapeutics by 57.2% in the second quarter. Bank of New York Mellon Corp now owns 134,877 shares of the company’s stock valued at $978,000 after purchasing an additional 49,102 shares during the period. Rhumbline Advisers increased its holdings in Larimar Therapeutics by 74.6% during the 2nd quarter. Rhumbline Advisers now owns 54,936 shares of the company’s stock worth $398,000 after acquiring an additional 23,475 shares during the period. Ballentine Partners LLC purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $137,000. Thoroughbred Financial Services LLC purchased a new stake in shares of Larimar Therapeutics in the second quarter worth $94,000. Finally, Squarepoint Ops LLC grew its position in Larimar Therapeutics by 174.6% during the second quarter. Squarepoint Ops LLC now owns 29,858 shares of the company’s stock worth $216,000 after buying an additional 69,858 shares in the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

See Also

Earnings History and Estimates for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.